Research Analysts Set Expectations for LMAT FY2025 Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of LeMaitre Vascular in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the medical instruments supplier will earn $2.22 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $96.00 price objective on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share.

Several other brokerages also recently commented on LMAT. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Down 1.7 %

Shares of LMAT stock opened at $98.00 on Wednesday. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 53.55, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a 52 week low of $56.04 and a 52 week high of $109.58. The firm has a 50 day moving average of $98.28 and a 200-day moving average of $92.19.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 EPS.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. raised its stake in shares of LeMaitre Vascular by 8.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,950 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 228 shares during the period. KBC Group NV increased its holdings in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 410 shares during the last quarter. Linden Thomas Advisory Services LLC increased its holdings in LeMaitre Vascular by 5.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 34,482 shares of the medical instruments supplier’s stock worth $3,177,000 after acquiring an additional 1,834 shares during the last quarter. SG Americas Securities LLC purchased a new stake in LeMaitre Vascular in the 4th quarter worth about $158,000. Finally, Albion Financial Group UT increased its holdings in LeMaitre Vascular by 5.7% in the 4th quarter. Albion Financial Group UT now owns 3,796 shares of the medical instruments supplier’s stock worth $350,000 after acquiring an additional 204 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.